Biogen (BIIB) Cash & Current Investments (2009 - 2026)

Biogen has reported Cash & Current Investments for 18 years, with the latest figure at $1.3 billion in Q2 2026.

• On a quarterly basis, Cash & Current Investments fell 53.42% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 53.42% decrease from a year earlier, with the FY2025 full-year figure at $3.8 billion, up 60.66% from the prior year.
• Cash & Current Investments was $1.3 billion for Q2 2026 at Biogen, down from $4.3 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $6.1 billion in Q2 2023, with the low at $1.0 billion in Q4 2023.
• Average Cash & Current Investments over 5 years is $3.3 billion, with a median of $3.3 billion recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments tumbled 78.69% in 2024, then jumped 141.84% in 2025.
• Over 5 years, Cash & Current Investments stood at $4.9 billion in 2022, then tumbled by 78.54% to $1.0 billion in 2023, then surged by 126.21% to $2.4 billion in 2024, then jumped by 60.66% to $3.8 billion in 2025, then plunged by 66.32% to $1.3 billion in 2026.
• The last three Cash & Current Investments figures came in at $1.3 billion (Q2 2026), $4.3 billion (Q1 2026), and $3.8 billion (Q4 2025), per Business Quant data.